WO2014024201A1 - Regulate and manage blood glucose levels of a subject by promoting cell metabolism with the application of low frequency (20 khz to 70 khz ) airborne ultrasound waves and a machine to produce the airborne ultrasound waves therefor - Google Patents
Regulate and manage blood glucose levels of a subject by promoting cell metabolism with the application of low frequency (20 khz to 70 khz ) airborne ultrasound waves and a machine to produce the airborne ultrasound waves therefor Download PDFInfo
- Publication number
- WO2014024201A1 WO2014024201A1 PCT/IN2012/000642 IN2012000642W WO2014024201A1 WO 2014024201 A1 WO2014024201 A1 WO 2014024201A1 IN 2012000642 W IN2012000642 W IN 2012000642W WO 2014024201 A1 WO2014024201 A1 WO 2014024201A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- section
- microcontroller
- dac
- aerostimulator
- digital
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0218—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement
- A61H23/0236—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement using sonic waves, e.g. using loudspeakers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0034—Skin treatment
Definitions
- the present invention relates generally to the application of low frequency airborne ultrasound waves ( 20 Khz to 70 Khz) with the help of a aerostimulator particularly a non-invasive personal aerostimulator to regulate / manage blood glucose levels / promote cell metabolism of a subject throughout the day.
- Ultrasound which is routinely used for diagnostic imaging applications worldwide is now being adopted in various fields of drug delivery systems and other therapeutic use. Interactions of acoustic ultrasound with biological tissues play an important role in biomedical applications of ultrasound. Low intensity ultrasound is known to permeate the skin, modulate the cell membrane and alter its properties possibly activating signal transduction pathways. The energy absorbed by the enzymes from the ultrasound effects the overall function of the cell. This could lead to the increased production of protein or reduce the depletion of beta cells associated with insulin.
- GlybetaC -Digital uses the goodness of airborne ultrasonic energy to enhance the cell permeability and help in the transportation of drugs into them thereby increasing the effectiveness of existing drugs.
- GlybetaC-Digital Aerostimulator uses the principle of transmitting low frequency airborne ultrasound non invasively on humans to promote cell metabolism. The vibratory motion causes energy propagation which brings about a series of cascading effects on the cell membrane. Low frequency ultrasound is capable of maximum penetration and its energy is absorbed by the tissues, nerves etc. This changes the rate of macromolecular synthesis and causes ultrastructural changes within the cells. Enhanced stimulation of the cells by airborne ultrasound allows the permeability of the cells to increase and helps transport of the drugs into them.
- the ultrasonic energy On passing through the tissue, the ultrasonic energy is absorbed at a rate proportional to the density of the tissue. Absorption of the ultrasound signal results in energy conversion to heat. While this heating effect is extremely small, some enzymes or chemical mediators mediate the activation of intracellular signaling and additional mechanical stimulation of the cell membranes occur too. Ultrasound serves to reestablish or normalize effective metabolic temperatures in areas or in regions where blood flow has been compromised; this effect, while subtle, may be biologically profound.
- the differential energy absorption of ultrasound also gives rise to the phenomenon of acoustic streaming, or the movement of fluid.
- the acoustic streaming and the resultant pressure may mechanistically advance signal-transduction pathways, a process referred to as mechanotransduction.
- mechanotransduction a process referred to as mechanotransduction.
- the introduction of an ultrasound signal stimulates a dynamic physical environment.
- the enhanced movement of the fluid increases the processes of nutrient delivery and waste removal i.e Endocytosis and Exocytosis in the cells. It is likely that the acoustic signal is recognized and is strongly influential in the biology of the cells.
- Optimal ultrasound has the capability to open, holes in cell membranes like the transport proteins integrated into the cell membranes. These proteins are transported by diffusion or assisted by the concentration gradient across the cell.
- the drugs are absorbed inside the cells by a process akin to Endocytosis, wherein the ultrasound assisted drug is released or transported inside the cell by opening the cell membrane and releasing the drug inside.
- the drug delivery is maximized while cell viability is maintained.
- Cell membranes opened due to the above processes are closed immediately by the internal cellular patching process.
- Airborne Ultrasound waves Piezoelectric crystals are used for generating ultrasound waves.
- the crystals are deformed in response to high frequency signals applied to them in the form of electrical voltage and ultrasonic waves are generated .
- GlySetaC Aerostimulator uses state of the art quartz crystal technology to generate ultrasonic sound waves which gives a micromassage and thermal effect in tissues and produces mechanical stimulation of the receptors in the human body,
- GiyBetac Aerostimulator has variable modulations with a wide frequency bandwidth to allow a variety of waveforms which ensure that the body tissues do not develop immunity to any specific frequency.
- GlyBe!aC Aerostimulator uses the principle of transmitting low frequency airborne ultrasound non !fwasiveiy on humans to promote cell metabolism.
- Giucose is an essential substrate tor the metabolism of most cells.
- the vibratory motion of ultrasound causes energy propagation which brings about a series of cascading effects on the ceil membrane.
- Low frequency ultrasound Is capable ol maximum penetration and its energy is absorbed by the tissues, nerves etc. This changes the rate of macromo!ecular synthesis and causes ultrastructural changes within the cells.
- Transmission of ultrasound waves produces a micromassage effect in tissues and enhances mechanical stimulation of the receptors in human body. Enhanced stimulation of the cells by airborne ultrasound allows the permeability of the cells to improve and helps transport of glucose into them.
- the ultrasonic energy On passing through the tissue, the ultrasonic energy is absorbed at a rate ' proportional to the density of the tissue. Absorption of the ultrasound signal results in energy conversion to heat. This heating effect is extremely small because of pulsed form of transmission.
- Ultrasound have Thermal and non thermal effects on the tissues. Energy attenuated by tissues ieads to thermal increase and this thermal energy allows Facilitated diffusion of giucose thereby helping the transport of glucose into cells.
- Non thermal effects of Ultrasound are Stable Cavitation and Acoustic streaming. These mechanisms cause movements and transfers of intracellular and extracellular ions.
- FIG. 1 A shows the block diagram of the digital aero stimulator
- FIG. IB shows the different essential parts of the digital aero stimulator
- FIG. 2 shows the Input bridge section of the digital aero stimulator
- FIG. 3 shows the circuit diagram of microcontroller power section
- FIG. 4 shows the details of micro controller section
- FIG. 5. shows the DAC for wave generation
- FIG. 6 shows the voltage gain opamp section
- FIG. 7 shows the Regulated AC using LM317
- FIG. 8 shows the ouput drive section of the digital aero stimulator
- FIG. 9 shows the MosFET H-Bridge Section
- FIG.10 to 13 explain the thermal action and the non-thermal action of the ultrasound wave.
- FIGS. 1 through 9 there is shown the details of the digital aero stimulator.
- GlyBetaC DIGITAL comprises of the following sections
- UA78M33 Provides regulated 3.3VDC for microcontroller section.
- Cap C3, C4 are used as Filter Caps.
- LED L2 Serves the purpose of Indication.
- Microcontroller Used is MSP430F5310.
- PINs TEST, TDO, TDI, TMS, TCK, RST are used as JTAG pins to Program the firmware into microcontroller.
- Yl - is Crystal Oscillator which gives 16MHz Clock Frequency for Micro.
- Caps CI & C2 are used as Decoupling Caps for Crystal Oscillator supply.
- the Microcontroller (section.1-3) updates DAC with values stored in its look-up table to form a full sine wave at its output.
- the opamp is configured as a non inverting single supply gain stage.
- the Feedback resistor (R14) and Input resistance (R15) decide the gain of
- the output of the opamp section.1-5 is fed to the adjust pin of the LM317.
- Driver IC U5 (UCC27425P) drives Sweep signal from microcontroller.
- CAPs CI 6, C6 & C7 are used as decoupling Capacitors for UCC27425P.
- Zener Diodes - Z2 & Z3 are used voltage regulator for UCC27425.
- H-Bridge Used here is ZXMHC3 AO 1 T8 (3 Amp, 30V) (Zetex Make).
- CAPs C5, C26 are used as Decoupling capacitors for H-Bridge.
- Diodes D7 & D5 are used to cut down offset voltage.
- Output section is powered with 100Hz full wave rectified labeled 20Vpp_AC_100Hz - Section.1 -6 .
- GlybetaC-Digital Aerostimulator consists of a console with a Quartz crystal transducer fixed to it.
- GlybetaC-Digital Aerostimulator is made as per the guidelines / safety standards laid down by
- Gly BetaC Aerostimulator improves and enhances quality of life:
- Digital aerostimulator is not intended to replace medication but to enhance its effect.
- the effectiveness can be maintained by increasing or decreasing time of exposure depending upon the type of people. Obese people can use the machine for longer time compared to normal people.
- digital aerostimulator is not intended to be used as medical advice, or to diagnose, treat, cure, or prevent any disease nor should it be used for therapeutic purposes or a substitute for a Health professional's advice.
Abstract
A digital aerostimulator or airborne ultrasound wave emitter comprising an Input Bridge Section for supply of unregulated full wave (V dc) to a voltage regulator, op-amp and sine wave generator. A Microcontroller Power Section comprising a voltage regulator UA78M33 and capacitors for signal filtering and a LED for status indication wherein the output from input bridge V dc goes as input to UA78M33. Further it comprises a Microcontroller Section centered around a microcontroller MSP430F2121IDW and a DAC (digital to analog converter) for full wave sine generation which is operationally coupled to the microcontroller. The Microcontroller section updates DAC with values stored in its look-up table to form a full sine wave at its output. Further the device comprises an OP-AMP voltage amplification stage and a regulated AC-current amplification stage, an Output Driver section, a MosFET H-Bridge section and an ultrasound transducer.
Description
REGULATE AND MANAGE BLOOD GLUCOSE LEVELS OF A SUBJECT BY PROMOTING CELL METABOLISM WITH THE APPLICATION OF LOW FREQUENCY
(20 KHZ TO 70 KHZ ) AIRBORNE ULTRASOUND WAVES AND A MACHINE TO PRODUCE THE AIRBORNE ULTRASOUND WAVES THEREFOR
FIELD OF THE INVENTION:
The present invention relates generally to the application of low frequency airborne ultrasound waves ( 20 Khz to 70 Khz) with the help of a aerostimulator particularly a non-invasive personal aerostimulator to regulate / manage blood glucose levels / promote cell metabolism of a subject throughout the day.
BACKGROUND OF THE INVENTION:
Ultrasound which is routinely used for diagnostic imaging applications worldwide is now being adopted in various fields of drug delivery systems and other therapeutic use. Interactions of acoustic ultrasound with biological tissues play an important role in biomedical applications of ultrasound. Low intensity ultrasound is known to permeate the skin, modulate the cell membrane and alter its properties possibly activating signal transduction pathways. The energy absorbed by the enzymes from the ultrasound effects the overall function of the cell. This could lead to the increased production of protein or reduce the depletion of beta cells associated with insulin.
Utilizing the above knowledge a revolutionary product conceived with the sole purpose of regulating the blood glucose levels of millions of Diabetics world over and benefits the society on the whole. GlybetaC -Digital uses the goodness of airborne ultrasonic energy to enhance the cell permeability and help in the transportation of drugs into them thereby increasing the effectiveness of existing drugs.
GlybetaC-Digital Aerostimulator uses the principle of transmitting low frequency airborne ultrasound non invasively on humans to promote cell metabolism. The vibratory motion causes energy propagation which brings about a series of cascading effects on the cell membrane. Low frequency ultrasound is capable of maximum penetration and its energy is absorbed by the tissues, nerves etc. This changes the rate of macromolecular synthesis and causes ultrastructural changes within the cells. Enhanced stimulation of the cells by airborne ultrasound allows the permeability of the cells to increase and helps transport of the drugs into them.
On passing through the tissue, the ultrasonic energy is absorbed at a rate proportional to the density of the tissue. Absorption of the ultrasound signal results in energy conversion to heat. While this heating effect is extremely small, some enzymes or chemical mediators mediate the activation of intracellular signaling and additional mechanical stimulation of the cell membranes occur too. Ultrasound serves to reestablish or normalize effective metabolic temperatures in areas or in regions where blood flow has been compromised; this effect, while subtle, may be biologically profound.
The differential energy absorption of ultrasound also gives rise to the phenomenon of acoustic streaming, or the movement of fluid. The acoustic streaming and the resultant pressure may mechanistically advance signal-transduction pathways, a process referred to as mechanotransduction. Thus, the introduction of an ultrasound signal stimulates a dynamic physical environment. The enhanced movement of the fluid increases the processes of nutrient delivery and waste removal i.e Endocytosis and Exocytosis in the cells. It is likely that the acoustic signal is recognized and is strongly influential in the biology of the cells.
Optimal ultrasound has the capability to open, holes in cell membranes like the transport proteins integrated into the cell membranes. These proteins are transported by diffusion or assisted by the concentration gradient across the cell. The drugs are absorbed inside the cells by a process akin to Endocytosis, wherein the ultrasound assisted drug is released or transported inside the cell by opening the cell membrane and releasing the drug inside. The drug delivery is maximized while cell viability is maintained. Cell membranes opened due to the above processes are closed immediately by the internal cellular patching process.
Traditional methods of drug delivery are often not suitable for large molecules, such as proteins and DNA, underscoring the need for improved drug delivery strategies. Ultrasound holds considerable clinical promise in this realm, experts say.
OBJECT OF THE INVENTION:
It is therefore an object of the invention to provide a method of regulating/managing blood glucose levels of a subject by promoting cell metabolism with the application of low frequency ( 20 Khz to 70 Khz) airborne ultrasound wave throughout the day with the help of a non-invasive personal aerostimulator.
Further object of the present invention will be clear from the following description of the invention.
Acoustic vibrations thai are transmitted over 20 KHz frequency in air are called Airborne Ultrasound waves, Piezoelectric crystals are used for generating ultrasound waves. The crystals are deformed in response to high frequency signals applied to them in the form of electrical voltage and ultrasonic waves are generated .
GlySetaC Aerostimulator uses state of the art quartz crystal technology to generate ultrasonic sound waves which gives a micromassage and thermal effect in tissues and produces mechanical stimulation of the receptors in the human body,
GiyBetac Aerostimulator has variable modulations with a wide frequency bandwidth to allow a variety of waveforms which ensure that the body tissues do not develop immunity to any specific frequency.
Principle of working:
GlyBe!aC Aerostimulator uses the principle of transmitting low frequency airborne ultrasound non !fwasiveiy on humans to promote cell metabolism. Giucose is an essential substrate tor the metabolism of most cells. The vibratory motion of ultrasound causes energy propagation which brings about a series of cascading effects on the ceil membrane. Low frequency ultrasound Is capable ol maximum penetration and its energy is absorbed by the tissues, nerves etc. This changes the rate of macromo!ecular synthesis and causes ultrastructural changes within the cells. Transmission of ultrasound waves produces a micromassage effect in tissues and enhances mechanical stimulation of the receptors in human body. Enhanced stimulation of the cells by airborne ultrasound allows the permeability of the cells to improve and helps transport of glucose into them.
On passing through the tissue, the ultrasonic energy is absorbed at a rate ' proportional to the density of the tissue. Absorption of the ultrasound signal results in energy conversion to heat. This heating effect is extremely small because of pulsed form of transmission.
Ultrasound have Thermal and non thermal effects on the tissues. Energy attenuated by tissues ieads to thermal increase and this thermal energy allows Facilitated diffusion of giucose thereby helping the transport of glucose into cells.
Thus helps the action potential and insulin release.
It also helps in transport of glucose into the cell.
Thermal action of Ultrasound apart from helping transport of glucose into the cell also helps to reestablish or normalize effective metabolic temperature tn the areas where blood flow has been compromised especially m the lower limbs. This effect, while subtle, may be biologically profound.
Non thermal effects of Ultrasound are Stable Cavitation and Acoustic streaming. These mechanisms cause movements and transfers of intracellular and extracellular ions. An increase in intercellular ion transfers Ieads to changes in membrane permeability which helps transportation of glucose into cell thereby helping to regulate blood glucose levels.
The thermal action and the non-thermal action of the ultrasound wave is explained in figs.10, 11 , 12 and 13.
BRIEF DESCRIPTION OF THE DRAWINGS:
The invention will now be described with respect to the non-limiting figures in the accompanying drawings, in which
FIG. 1 A shows the block diagram of the digital aero stimulator
FIG. IB shows the different essential parts of the digital aero stimulator
FIG. 2 shows the Input bridge section of the digital aero stimulator
FIG. 3 shows the circuit diagram of microcontroller power section
FIG. 4 shows the details of micro controller section
FIG. 5. shows the DAC for wave generation
FIG. 6 shows the voltage gain opamp section
FIG. 7 shows the Regulated AC using LM317
FIG. 8 shows the ouput drive section of the digital aero stimulator,
FIG. 9 shows the MosFET H-Bridge Section
FIG.10 to 13 explain the thermal action and the non-thermal action of the ultrasound wave.
Like reference numerals refer to like parts throughout the several views of the drawings.
DETAIL DESCRIPTION OF THE INVENTION
Referring to FIGS. 1 through 9, there is shown the details of the digital aero stimulator.
GlyBetaC DIGITAL comprises of the following sections
1.Input Bridge Section
2. Microcontroller Power Section
3. Microcontroller Section
4.12- BIT DAC for full wave sine generation
5. OP AMP for Voltage Amplification
6. Regulated AC- Current Amplification Stage
7.0utput Driver Section
8. MosFet H-Bridge Section
9. Transducer
The details of above sections are given in fig 1.
The bridge supplies unregulated full wave (V_dc) to-
1. Input of UA78M33 Voltage Regulator (fig. 3)
2. Input of TLE2141 OPAMP.
3. Input of LM317 Voltage Regulator here used for Sine wave Generation. Microcontroller Power Section
1. Output from Input Bridge & Regulatio n section V dc goes as input to UA78M33.
2. UA78M33 Provides regulated 3.3VDC for microcontroller section.
3. Cap C3, C4 are used as Filter Caps.
4. LED L2 Serves the purpose of Indication.
Microcontroller Section
This section is centered around Microcontroller MSP430F2121IDW (Texas Instrument)
1. Microcontroller Used is MSP430F5310.
2. Works on 3.3VDC.
3. All Capacitors are used as Decoupling caps for Micro.
4. PINs TEST, TDO, TDI, TMS, TCK, RST are used as JTAG pins to Program the firmware into microcontroller.
5. Yl - is Crystal Oscillator which gives 16MHz Clock Frequency for Micro.
6. Caps CI & C2 are used as Decoupling Caps for Crystal Oscillator supply.
7. SI - Switch - for Reset Purpose.
8. JP2 - 8Pin Header for JTAG.
9. P2.5 - TEST - used as PPM LED.
10. P4.0 - SCLK_DAC - Used to update DAC with full wave sine data.
11. P4.1— Din DAC - Used to update DAC with full wave sine data.
12. P4.2 - Not Used.
13. P4.3 - FS - DAC - Used to update DAC with full wave sine data.
14. P4. 4 - TX-TTL -Used to configure parameters.
15. P4. 5 - RX-TTL -Used to configure parameters.
16. P4.7 / P4.6 - FREQ SWEEPl - 20KHz To 60KHz Freq Sweep on this PIN.
17. P1.0 - 100Hz_Scan - Not Used.
18. PI .5 - Sweep_Driver_En - Used To enable / disable Driver UCC27425.
19. PI.6 - Switch Set - Used to Set Dafault parameters on machine boot up.
20. PI .7 - PPM_LED - Used as PPM LED.
21. P2.0 - Switch - Not Used.
12- BIT DAC for full wave sine generation
1. The Microcontroller (section.1-3) updates DAC with values stored in its look-up table to form a full sine wave at its output.
2. 180 value of DAC code data make up the full sine wave.
Wave=Vp*sin(angle)*256/(2*DAC_Ref_Vol)
OPAMP for Voltage Amplification
1. The opamp is configured as a non inverting single supply gain stage.
2. The Feedback resistor (R14) and Input resistance (R15) decide the gain of
the opamp.
3. Hardware Gain after opamp = (1 + Rf/Ri) = 1+ 100k/6.8k
Regulated AC- Current Amplification Stage
1. The output of the opamp section.1-5 is fed to the adjust pin of the LM317.
(3 terminal voltage adjustable voltage regulator)
2. The LM317's ability to follow the Adjust pin at the output gives the
full sine wave with the required current(~l .5A) .
3. This powers the H-Bridge Section as described in section.1-8.
Output Driver Section
1. Driver IC U5 (UCC27425P) drives Sweep signal from microcontroller.
2. CAPs CI 6, C6 & C7 are used as decoupling Capacitors for UCC27425P.
3. Zener Diodes - Z2 & Z3 are used voltage regulator for UCC27425.
4. Output from this driver corresponds to Vdriver (+12V).
5. Output from this section goes as gate drive for MosFet Section.
MosFet H-Bridge Section
1. H-Bridge Used here is ZXMHC3 AO 1 T8 (3 Amp, 30V) (Zetex Make).
2. CAPs C5, C26 are used as Decoupling capacitors for H-Bridge.
3. Diodes D7 & D5 are used to cut down offset voltage.
4. Output section is powered with 100Hz full wave rectified labeled 20Vpp_AC_100Hz - Section.1 -6 .
5. This gives a 100Hz modulated wave with 20 KHz - 60 KHz encompassed frequency sweep.
System Specifications:
GlybetaC-Digital Aerostimulator consists of a console with a Quartz crystal transducer fixed to it.
Specifications:
1. Power Supply 230 Volts AC 50 Hz
2. Frequency Between 20Khz and 65 KHz
3. Pulse Rate < 25 Pulse/Min.
4. Sound Pressure Output< 110 dB
5. Dimensions 225mm * 65mm * 115mm
6. Weight 1250gms. Safety:
GlybetaC-Digital Aerostimulator is made as per the guidelines / safety standards laid down by
American Conference of Governmental and Industrial Hygienists
(ACGIH)
• International Commission on Non Ionizing Radiation Protection (ICNIRP)
• World Health Organization.
• Bureau of Radiation and Medical Devices, Canada and many others.
Test Reasults conducted on Gly BetaC using top of the Rion range Sound Level meters and 1/3 octave band real time analyzer SA-78(JAPAN) are reproduced in drawing sheet 1-5.
Instructions for safe ase of :€ilyBetac Aerostiifiolaton
• 0.n day- Ϊ : 1:'akc a fasting glucose test before you start using
GlyBitac,
• Plug in the machine to a- standard 23D V AC -electrical outlet
• Sit at a minimum distance of 4 feet aatl a maximum .distance of 6
feet away from the machine for minimum of .1.0: minutes and
maximum, of 2© minutes-. Use GlvBetac 20 eiiiwles before or after
talcing food .You -can Cisatioue- .to do ysur routiner work: like
listening 'to. music, watching, television etc while sitting, before the
unit
• On day 2: Check your fasting glucose levels. Observe the
difference and accordingly use the medication,.
• Make sure that the doors are closed,
• Repeat steps I to 5 for day 3- and check the Easting Glucose levels
again on day 3.
• You can use lite GiyBetae any irumher of times per day with
mimrowm .gap of 4 hxs.
• Use GlybetaC-Digital regularly for a week. After one week you can use the machine twice a week or as desired by you.
• Never keep the machine in the electrical outlet after the use.
• Do not tamper with the machine as it may malfunction.
• You can not hear any sound or feel any vibrations coming from the machine as you can not hear ultrasound. Stop using the machine if you hear any unusual sound coming from it and call for immediate service.
• Keep the machine away from children
ADVANTAGES OF THE INVENTION.
Gly BetaC Aerostimulator improves and enhances quality of life:
Enhances the potency of anti-diabetic medication in controlling blood glucose.
Faster healing of diabetic foot ulcers.
Reduces fatigue, tiredness and muscular pains.
Reduces burning under the foot.
Increases flexibility of joints.
Improves blood circulation
Improves vision.
Increases energy levels.
Improves strength of lower limbs.
Improves quality of sleep.
It is also found that after using digital aerostimulator the intake of medication required reduced substantially.
In addition to this the following advantages are also found:
Improves Cell Permeability thereby enhancing the absorption of various drugs by human cells including larger molecules.
Can be used as a arthritic pain management device.
Can be used to enhance the absorption of skin care medicines by human skin for treatment of skin diseases / beauty treatment.
Because of repetitive stimulation by high frequency sound waves can be used for improving the metabolism of human cells.
IMPORTANT
Digital aerostimulator is not intended to replace medication but to enhance its effect.
It does not have any side effects so it wont affect if somebody else also sits in the room when the machine is on. However it is advised that simulation is taken only by the diabetics.
There is no food restrictions. You can continue with your usual diet as prescribed by the doctor.
There will be some variations in effect depending on the type of people.
The effectiveness can be maintained by increasing or decreasing time of exposure depending upon the type of people. Obese people can use the machine for longer time compared to normal people.
Caution:
It is strongly recommended to check your blood glucose levels before and after exposure
to digital aerostimulator. Accordingly regulate the intake of anti-diabetic drugs as per the advice of your doctor. digital aerostimulator is not intended to be used as medical advice, or to diagnose, treat, cure, or prevent any disease nor should it be used for therapeutic purposes or a substitute for a Health professional's advice.
While specific embodiments of the invention have been shown and described herein for purposes of illustration, the protection afforded by any patent which may issue upon this application is not strictly limited to the disclosed embodiments; but rather extends to all structures and arrangements which fall fairly within the scope of the claims which are appended hereto.
Claims
1. A digital aerostimulator comprising
An Input Bridge Section for supply of unregulated full wave (V_dc) to a voltage regulator ,ορ-amp and sine wave generator ,
A Microcontroller Power Section comprising a voltage regulator UA78M33 and capacitors for filtering and led for indication where in output from input bridge V_dc goes as input to UA78M33, a Microcontroller Section centered around a microcontroller MSP430F2121IDW, a DAC for full wave sine generation which is operationally coupled to the microcontroller, the Microcontroller section updates DAC with values stored in its look-up table to form a full sine wave at its output, an OP-AMP voltage amplification stage and a regulated AC- current amplification stage, an Output Driver section , a MosFET H-Bridge section and a transducer.
2. A digital aerostimulator as claimed in claim 1 wherein the input bridge supplies unregulated full wave (V_dc) to the input of UA78M33 Voltage Regulator (fig. 3), input of TLE2141 OP AMP and the input of LM317 Voltage Regulator which is used for Sine wave Generation.
3. A digital aerostimulator as claimed in claim 1 wherein the microcontroller power section comprises a voltage regulator UA78M33 and capacitors for filtering and led LI for indication where in output from Input Bridge & Regulation section V_dc goes as input to
UA78M33,UA78M33 provides regulated 3.3VDC for the microcontroller section.
4. A digital aerostimulator as claimed in claim 1 wherein the Microcontroller Section comprises a Microcontroller MSP430F5310 which works on 3.3VDC,all the capacitors are used as decoupling capacitors for Micro, PINs TEST, TDO, TDI, TMS, TCK, RST are used as JTAG pins to Program the firmware into microcontroller^ Crystal Oscillator Yl which gives 16MHz clock frequency for Micro ,capacitors CI & C2 are used as decoupling caps for crystal oscillator supply ,a switch SI for Reset, JP 2 - 8 Pin Header for JTAG, P2.5 - TEST - used as PPM LED, P4.0 - SCLK_DAC - Used to update DAC with full wave sine data, P4.1 - Din DAC - Used to update DAC with full wave sine data, P4.2 - Not Used, P4.3 - FS - DAC - Used to update DAC with full wave sine data, P4. 4 - TX-TTL -Used to configure parameters, P4. 5 - RX-TTL -Used to configure parameters, P4.7 / P4.6 - FREQ SWEEPl - 20KHz To 60KHz Freq Sweep on this PIN, PI .0 - 100Hz_Scan - Not Used, PI .5 - Sweep_Driver_En - Used To enable / disable Driver UCC27425, PI .6 - Switch Set - Used to Set Default parameters on machine boot up, PI.7 - PPM LED - Used as PPM LED and
P2.0 - Switch - Not Used.
5. A digital aerostimulator as claimed in claim 1 wherein DAC is 12 bit, the microcontroller updates DAC with values stored in its look-up table to form a full sine wave at its output and 180 value of DAC code data make up the full sine wave with the following relationship
Wave=Vp*sin(angle)*256/(2*DAC_Ref_Vol).
6. A digital aerostimulator as claimed in claim 1 wherein op-amp voltage amplification stage comprises an op-amp configured as a non inverting single supply gain stage and the feedback resistor (R14) and input resistance (R15) decide the gain of the opamp such that Hardware Gain after op-amp = (1 + Rf/Ri) = 1+ 100k/6.8k = 15.706.
7. A digital aerostimulator as claimed in claim 1 wherein the regulated AC- current amplification stage comprises a 3 terminal voltage adjustable voltage regulator LM 317,the output of the op-amp stage is fed to the adjust pin of the LM317
, the LM317 has the ability to follow the adjust pin at the output gives the full sine wave with the required current(~1.5A) which powers the H-Bridge Section.
8. A digital aerostimulator as claimed in claim 1 wherein the output Driver section comprises a Driver IC U5 (UCC27425P) which drives Sweep signal from microcontroller, CAPs CI 6, C6 & C7 are used as decoupling Capacitors for UCC27425P, Zener Diodes - Z2 & Z3 are used voltage regulator for UCC27425,the output from this driver corresponds to Vdriver (+12V) and output from this section goes as gate drive for MosFet Section.
9. A digital aerostimulator as claimed in claim 1 wherein the MosFET H-Bridge section comprises H-Bridge ZXMHC3A01T8 (3Amp, 30V) (Zetex make),capacitors C5, C26 are used as decoupling capacitors for H-Bridge, diodes D7 & D5 are used to cut down offset voltage, the output section is powered with 100Hz full wave rectified labeled
20Vpp_AC_100Hz and this gives a 100Hz modulated wave with 20 KHz - 60 KHz encompassed frequency sweep.
10. A method of regulating /Managing blood glucose levels of a subject by promoting cell metabolism with the application of low frequency ( 20Khz to 70 Khz) airborne ultrasound wave comprising the steps of
powering on the digital aerostimulator,
making the subject sitting at a minimum distance of 4 feet and a maximum distance of 6 feet away from the aerostimulator for mimimum of 10 minutes and maximum of 20 minutes and repeating the same after a minimum gap of 4 hrs.
11.A digital aerostimulator substantially described as herein with reference to the figures of the accompanying drawings.
Dated this 01st day of August, 2012
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2251/MUM/2012 | 2012-08-06 | ||
| IN2251MU2012 | 2012-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014024201A1 true WO2014024201A1 (en) | 2014-02-13 |
Family
ID=47844416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2012/000642 WO2014024201A1 (en) | 2012-08-06 | 2012-09-26 | Regulate and manage blood glucose levels of a subject by promoting cell metabolism with the application of low frequency (20 khz to 70 khz ) airborne ultrasound waves and a machine to produce the airborne ultrasound waves therefor |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014024201A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9886556B2 (en) | 2015-08-20 | 2018-02-06 | Aseko, Inc. | Diabetes management therapy advisor |
| US9892234B2 (en) | 2014-10-27 | 2018-02-13 | Aseko, Inc. | Subcutaneous outpatient management |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| WO2020186073A1 (en) * | 2019-03-12 | 2020-09-17 | General Electric Company | Neuromodulation to target glucose transporter and/or incretin pathways |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5460595A (en) * | 1993-06-01 | 1995-10-24 | Dynatronics Laser Corporation | Multi-frequency ultrasound therapy systems and methods |
| US20040013420A1 (en) * | 2002-07-17 | 2004-01-22 | Minolta Co., Ltd. | Driving device, position controller provided with driving device, and camera provided with position controller |
| US20080281238A1 (en) * | 2007-05-09 | 2008-11-13 | Tsutomu Oohashi | Oscillation representing system for effectively applying hypersonic sound |
-
2012
- 2012-09-26 WO PCT/IN2012/000642 patent/WO2014024201A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5460595A (en) * | 1993-06-01 | 1995-10-24 | Dynatronics Laser Corporation | Multi-frequency ultrasound therapy systems and methods |
| US20040013420A1 (en) * | 2002-07-17 | 2004-01-22 | Minolta Co., Ltd. | Driving device, position controller provided with driving device, and camera provided with position controller |
| US20080281238A1 (en) * | 2007-05-09 | 2008-11-13 | Tsutomu Oohashi | Oscillation representing system for effectively applying hypersonic sound |
Non-Patent Citations (2)
| Title |
|---|
| "GlyBetaC Brochure", 2 March 2011 (2011-03-02), Website of MASER ELECTRONICS (P) LTD, XP055063086, Retrieved from the Internet <URL:http://web.archive.org/web/20110302105935/http://www.maserindia.com/pdf/GlyBetaC_Brochure.pdf> [retrieved on 20130515] * |
| "GlyBetaC product page", 18 July 2010 (2010-07-18), Website of MASER ELECTRONICS (P) LTD, XP055063090, Retrieved from the Internet <URL:http://web.archive.org/web/20100718170828/http://www.maserindia.com/Glybetac.html> [retrieved on 20130515] * |
Cited By (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US11733196B2 (en) | 2012-09-11 | 2023-08-22 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9483619B2 (en) | 2012-09-11 | 2016-11-01 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US11131643B2 (en) | 2012-09-11 | 2021-09-28 | Aseko, Inc. | Method and system for optimizing insulin dosages for diabetic subjects |
| US10629294B2 (en) | 2012-09-11 | 2020-04-21 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US10410740B2 (en) | 2012-09-11 | 2019-09-10 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9773096B2 (en) | 2012-09-11 | 2017-09-26 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9811638B2 (en) | 2012-09-11 | 2017-11-07 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US10102922B2 (en) | 2012-09-11 | 2018-10-16 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9965596B2 (en) | 2012-09-11 | 2018-05-08 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US10453568B2 (en) | 2014-01-31 | 2019-10-22 | Aseko, Inc. | Method for managing administration of insulin |
| US11621074B2 (en) | 2014-01-31 | 2023-04-04 | Aseko, Inc. | Insulin management |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US11857314B2 (en) | 2014-01-31 | 2024-01-02 | Aseko, Inc. | Insulin management |
| US9965595B2 (en) | 2014-01-31 | 2018-05-08 | Aseko, Inc. | Insulin management |
| US11804300B2 (en) | 2014-01-31 | 2023-10-31 | Aseko, Inc. | Insulin management |
| US11783946B2 (en) | 2014-01-31 | 2023-10-10 | Aseko, Inc. | Method and system for insulin bolus management |
| US10255992B2 (en) | 2014-01-31 | 2019-04-09 | Aseko, Inc. | Insulin management |
| US11783945B2 (en) | 2014-01-31 | 2023-10-10 | Aseko, Inc. | Method and system for insulin infusion rate management |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| US9710611B2 (en) | 2014-01-31 | 2017-07-18 | Aseko, Inc. | Insulin management |
| US9604002B2 (en) | 2014-01-31 | 2017-03-28 | Aseko, Inc. | Insulin management |
| US10535426B2 (en) | 2014-01-31 | 2020-01-14 | Aseko, Inc. | Insulin management |
| US9504789B2 (en) | 2014-01-31 | 2016-11-29 | Aseko, Inc. | Insulin management |
| US9892235B2 (en) | 2014-01-31 | 2018-02-13 | Aseko, Inc. | Insulin management |
| US10811133B2 (en) | 2014-01-31 | 2020-10-20 | Aseko, Inc. | System for administering insulin boluses to a patient |
| US11490837B2 (en) | 2014-01-31 | 2022-11-08 | Aseko, Inc. | Insulin management |
| US11081233B2 (en) | 2014-01-31 | 2021-08-03 | Aseko, Inc. | Insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US11468987B2 (en) | 2014-01-31 | 2022-10-11 | Aseko, Inc. | Insulin management |
| US11158424B2 (en) | 2014-01-31 | 2021-10-26 | Aseko, Inc. | Insulin management |
| US11311213B2 (en) | 2014-01-31 | 2022-04-26 | Aseko, Inc. | Insulin management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| US11678800B2 (en) | 2014-10-27 | 2023-06-20 | Aseko, Inc. | Subcutaneous outpatient management |
| US11694785B2 (en) | 2014-10-27 | 2023-07-04 | Aseko, Inc. | Method and dosing controller for subcutaneous outpatient management |
| US10403397B2 (en) | 2014-10-27 | 2019-09-03 | Aseko, Inc. | Subcutaneous outpatient management |
| US10128002B2 (en) | 2014-10-27 | 2018-11-13 | Aseko, Inc. | Subcutaneous outpatient management |
| US9892234B2 (en) | 2014-10-27 | 2018-02-13 | Aseko, Inc. | Subcutaneous outpatient management |
| US11574742B2 (en) | 2015-08-20 | 2023-02-07 | Aseko, Inc. | Diabetes management therapy advisor |
| US10380328B2 (en) | 2015-08-20 | 2019-08-13 | Aseko, Inc. | Diabetes management therapy advisor |
| US9886556B2 (en) | 2015-08-20 | 2018-02-06 | Aseko, Inc. | Diabetes management therapy advisor |
| CN113557058A (en) * | 2019-03-12 | 2021-10-26 | 通用电气公司 | Neuromodulation targeting glucose transporters and/or incretin pathways |
| WO2020186073A1 (en) * | 2019-03-12 | 2020-09-17 | General Electric Company | Neuromodulation to target glucose transporter and/or incretin pathways |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014024201A1 (en) | Regulate and manage blood glucose levels of a subject by promoting cell metabolism with the application of low frequency (20 khz to 70 khz ) airborne ultrasound waves and a machine to produce the airborne ultrasound waves therefor | |
| US9433803B2 (en) | Method and system for destroying adipose tissue non-invasively and accelerating lipid metabolism | |
| US8469906B2 (en) | Therapeutic micro-vibration device | |
| TWI505825B (en) | Therapeutic micro-vibration device | |
| WO2007019491A3 (en) | Method and apparatus for producing therapeutic and diagnostic stimulation | |
| Ngo et al. | Development of low frequency (20–100 kHz) clinically viable ultrasound applicator for chronic wound treatment | |
| KR101007197B1 (en) | Apparatus for generating ultrasonics wave using piezoelectric sensor as band type | |
| KR200377073Y1 (en) | A complex therapy apparatus with laser for restoration of soft tissue, ultrasound, and vibration. | |
| CN204050691U (en) | A kind of ultrasonic therapeutic apparatus with control function | |
| KR102085220B1 (en) | Non-invasive treatment system using intermedium | |
| CN102397633A (en) | Method and device for treating vaginitis and adnexitis with ultrasonic wave | |
| CN102406982A (en) | Method and device for treating varicosity by using ultrasonic waves | |
| KR20030014548A (en) | Ultrasonic physical therapy device using herbal medicine | |
| CN102327673A (en) | Method and device for treating astriction by ultrasonic waves | |
| KR20130122857A (en) | Cupping device | |
| CN102406983A (en) | Method and device for treating encephalitis through ultrasonic waves | |
| CN102397151A (en) | Method and device for treating lumbar vertebrae diseases by using ultrasonic waves | |
| CN102397644A (en) | Method and device for treating enteroptosis and gastroptosis with ultrasonic wave and enteroptosis gastroptosis drug | |
| CN108355259A (en) | A kind of method and device that the sagging drug therapy stomach of ultrasonic wave combination stomach is sagging | |
| CN102397649A (en) | Method and device for treating diabetes by viagra or activated medicine with ultrasonic wave | |
| CN102397639A (en) | Method and device for treating tinnitus with ultrasonic wave | |
| KR20130122860A (en) | Using method of cupping device | |
| CN102397643A (en) | Method and device for treating psoriasis with ultrasonic wave | |
| CN102488977A (en) | Method and device for treating gastric ulcer through combination of ultrasonic wave and gastric ulcer medicines | |
| CN102397647A (en) | Method and device for treating proctoptosis with ultrasonic wave and proctoptosis drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12830889 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12830889 Country of ref document: EP Kind code of ref document: A1 |